This biotechnology company has released positive patent news.
The post Argenica (ASX:AGN) share price leapt 12% on US patent news today appeared first on The Motley Fool Australia. –
The biotechnology company’s shares were up 12.36% at the close, trading at 75 cents.
Argenica is working on new therapeutics to protect the brain after a patient suffers a stroke and other brain injuries.
Why is the Argenica share price up today?
Investors appeared to welcome news the company will be granted a US patent for its lead drug candidate ARG-007.
Argenica said this meant it would be able to use ARG-007 to treat people with stroke, traumatic brain injury and hypoxic-ischaemic encephalopathy (HIE). HIE is a condition that arises from not having enough oxygen or blood flow to the brain.
Argenica now plans to spearhead the drug’s commercialisation in the lucrative United States market.
The company advised it was given official “notice of allowance” for the patent, with the patent being formally granted within months.
The patent claim also covers the drug’s use for other diseases including multiple sclerosis, Parkinson’s disease, Huntington’s disease and epilepsy.
Comment from management
Argenica CEO Dr Liz Dallimore welcomed the announcement, saying:
The granting of this patent will strengthen our ability to enter into commercial negotiations with US pharmaceutical companies in the future.
The allowance of the claims in Argenica’s US patent are essential to potentially commercialising ARG-007 in our lead applications of stroke, TBI and HIE in the US.
Argenica Therapeutics share price snapshot
The Argenica share price has shot up in 2021, up 275%. The company listed on the ASX in June.
Over the past month, Argenica shares are up 50%. The company has a market capitalisation of about $35 million based on the current share price.
The post Argenica (ASX:AGN) share price leapt 12% on US patent news today appeared first on The Motley Fool Australia.
Should you invest $1,000 in Argenica Therapeutics right now?
Before you consider Argenica Therapeutics, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Argenica Therapeutics wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.